Pharmacokinetic Study of ARALAST (Human Alpha1- PI)

NCT00242385 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Alpha 1-Antitrypsin Deficiency

Interventions

BIOLOGICAL: Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor
BIOLOGICAL: Dose of 60 mg/kg alpha1-proteinase inhibitor

Sponsor

Baxalta now part of Shire

Collaborators

[object Object]